mitochondrial ORF of the 12S rRNA-c
A peptide made in mitochondria, the power plants of cells. Studied mainly in cells and animals. No such medicine exists.
This site is for information and education only. It does not promote or encourage the use or purchase of the substances described and is not medical advice. Many are not authorised as medicines and their safety has not been established. We sell nothing and have no ties to sellers. For health decisions, consult a doctor.
Safety. Papers tagged as studies with random groups measure MOTS-c in blood and do not give it to people. A 2026 review says very little is known about the safety of peptides like this one in people. Sources: study 1.
Risk of fakes. Reviews name it among peptides sold outside medical care. We found no tests of what these products contain. Sources: study 1.
| Where | Status | Checked | |
|---|---|---|---|
| PL | No approval | The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly. Source | Not yet |
| EU | No approval | The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026). Source | Not yet |
| US | No approval | No approved medicine. On 30 October 2026 the US health department (HHS) published a draft policy: it does not plan to act against pharmacies and doctors that make it on a prescription for a named patient, from an FDA-registered maker, until the FDA decides by rule. The draft is not binding, and comments close on 13 November 2026. Source | Not yet |
Scientific papers per year 2015–2025
These are search results. A count shows how much exists, not how good the studies are. 1 Nov 2026.
Not clear. Mouse studies only. Papers tagged as studies with random groups measure MOTS-c in blood and do not give it to people.
What doctors, patients and companies reported to the US medicines agency (FDA), and single cases described in medical journals. A report says what happened to someone after taking the substance. It does not prove the substance caused it, and it does not say how often it happens. Reports do not change any grade.
The FDA has no reports. That is not a sign of safety: almost nobody reports substances from outside pharmacies.
We found no published case of harm.
FDA reports come from openFDA, cases from a PubMed search. The editors have not read these cases yet. Titles stay in the original language. As of 3 Nov 2026.
Two pain medicine specialists go through the studies on BPC-157, TB-500, MOTS-c and GHK-Cu, the risk of contaminated products bought online, including heavy metals, and why a doctor should assess you first.
A short video in which the author rates popular peptides on a scale from S to F. His ratings are an opinion on whether something is worth taking. Our grades from A to E only say how strong the studies are. The comparison below is based on the video description.
| Studies | Kind of study | Who was studied | People | Duration | Dose as studied | Who paid |
|---|---|---|---|---|---|---|
| MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. | In animals | mice, Young, middle-aged and old mice | – | – | – | Unknown |
We found these papers automatically in PubMed. The editors have not read them yet, and they do not affect any grade. Titles stay in the original language.
The US health department published a draft policy under which it would not act against pharmacies that make MOTS-c on a prescription for a named patient, until the FDA decides by rule. It is still not an approved medicine.
